2025年3月最新中科院分区数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。近期推荐: | 热 SCI论文AI润色+人工QC服务 | 热 《新英格兰医学杂志》免费讲座 即刻报名! | 热 赛默飞基础学科研究有奖问卷 |
![]() |
基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | Drug Design Development and Therapy DRUG DES DEV THER (此期刊被最新的JCR期刊SCIE收录) LetPub评分 7.0
72人评分
我要评分
声誉 7.4 影响力 6.1 速度 8.9 | |||||||||||||||||||||||||||||||
期刊ISSN | 1177-8881 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||||||||
2023-2024最新影响因子 (数据来源于搜索引擎) | 4.7 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||||
实时影响因子 | 截止2024年12月31日:4.726 | |||||||||||||||||||||||||||||||
2023-2024自引率 | 2.10%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||
五年影响因子 | 4.8 | |||||||||||||||||||||||||||||||
JCI期刊引文指标 | 1.1 | |||||||||||||||||||||||||||||||
h-index | 48 | |||||||||||||||||||||||||||||||
CiteScore ( 2024年最新版) |
| |||||||||||||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||||||||||||
期刊官方网站 | https://www.dovepress.com/drug-design-development-and-therapy-journal | |||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||
期刊投稿网址 | https://www.dovepress.com/submit_step_1.php | |||||||||||||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Drug Design Development and Therapy的语言要求,还能让Drug Design Development and Therapy编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Drug Design Development and Therapy编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评(2篇) 论文致谢(2篇) 。
提交文稿 | |||||||||||||||||||||||||||||||
是否OA开放访问 | Yes | |||||||||||||||||||||||||||||||
OA期刊相关信息![]() | 文章处理费:需要( USD3300; ) 文章处理费豁免:查看说明 其他费用:没有 期刊主题关键词:drug design、drug safety、drug development、pharmaecuticals 相关链接:Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||||||||||||
通讯方式 | PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752 | |||||||||||||||||||||||||||||||
出版商 | Dove Medical Press Ltd. | |||||||||||||||||||||||||||||||
涉及的研究方向 | CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY | |||||||||||||||||||||||||||||||
出版国家或地区 | ENGLAND | |||||||||||||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||||||||||||
出版周期 | ||||||||||||||||||||||||||||||||
出版年份 | 2007 | |||||||||||||||||||||||||||||||
年文章数 | 256点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||
Gold OA文章占比 | 97.50% | |||||||||||||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 80.08% | |||||||||||||||||||||||||||||||
WOS期刊SCI分区 ( 2023-2024年最新版) | WOS分区等级:1区
| |||||||||||||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2025年3月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月升级版) |
| |||||||||||||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月旧的升级版) |
| |||||||||||||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1177-8881%5BISSN%5D | |||||||||||||||||||||||||||||||
平均审稿速度 | 网友分享经验: >12周,或约稿 | |||||||||||||||||||||||||||||||
平均录用比例 | 网友分享经验: | |||||||||||||||||||||||||||||||
版面费/APC文章处理费信息 | 文章处理费:需要( USD3300; ) 文章处理费豁免:查看说明 其他费用:没有 LetPub提供文章处理费(APC)支持服务,可以用人民币支付版面费啦! | |||||||||||||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Drug Design Development and Therapy顺利发表。
快看看作者怎么说吧:服务好评(2篇) 论文致谢(2篇) 。 提交文稿 | |||||||||||||||||||||||||||||||
期刊常用信息链接 |
|
|
|
|
中国学者近期发表的论文 | |
1. | Intranasal Insulin Diminishes Postoperative Delirium and Elevated Osteocalcin and Brain Derived Neurotrophic Factor in Older Patients Undergoing Joint Replacement: A Randomized, Double-Blind, Placebo-Controlled Trial Author: Yang, Mi; Zhou, Lei; Long, Ge; Liu, Xing; Ouyang, Wen; Xie, Chang; He, Xi Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 759-769. DOI: 10.2147/DDDT.S491300 PubMed DOI |
2. | Metagenomic Sequencing Combined with Metabolomics to Explore Gut Microbiota and Metabolic Changes in Mice with Acute Myocardial Infarction and the Potential Mechanism of Allicin Author: Gao, Yijie; Qin, Gaofeng; Liang, Shichao; Yin, Jiajie; Wang, Baofu; Jiang, Hong; Liu, Mengru; Luo, Fangyuan; Li, Xianlun Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 771-791. DOI: 10.2147/DDDT.S504884 PubMed DOI |
3. | Puerarin Ameliorates the Ferroptosis in Diabetic Liver Injure Through the JAK2/STAT3 Pathway Inhibition Based on Network Pharmacology and Experimental Validation Author: Fan, Xiaoxu; Liu, Shuangqiao; Yu, Jing; Hua, Jian; Feng, Yingtong; Wang, Zhen; Shen, Yiwei; Lan, Wei; Wang, Jingxia Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 737-757. DOI: 10.2147/DDDT.S487496 PubMed DOI |
4. | Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury Author: Zhu, Yan; Xu, Gaosi Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 857-875. DOI: 10.2147/DDDT.S498457 PubMed DOI |
5. | Asiaticoside Attenuates Chronic Restraint Stress-Induced Hippocampal CA1 Neuronal Ferroptosis via Activating BDNF/Nrf2/GPX4 Signaling Pathway Author: Zhou, An; Feng, Hao-Yinghua; Fan, Chu-Ning; Wang, Jun; Yuan, Zhong-Yu; Xu, Guang-Hui; Li, Cheng-Fu; Huang, Wei-Feng; Yi, Li-Tao Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 793-810. DOI: 10.2147/DDDT.S509208 PubMed DOI |
6. | Vincristine Regulates C/EBP-(3/TGF-(31 to Promote A1 Astrocyte Polarization and Induce Neuropathic Pain Author: Chen, Yunfu; Tang, Guangling; Lu, Jun; Tang, Sijie; Xiong, Xinglong; Chen, Chao; Pei, Lijian; Shi, Jing Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 827-840. DOI: 10.2147/DDDT.S504873 PubMed DOI |
7. | Recent Advances in Propranolol Hydrochloride Formulations for the Treatment of Infantile Hemangiomas Author: Ren, Lin; Xu, Xiaowen; Liu, Xianbin; Ning, Hong; Ding, Qian; Yang, Min; Liang, Tiantian Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 1163-1183. DOI: 10.2147/DDDT.S496847 PubMed DOI |
8. | Population Pharmacokinetics of Prolonged Infusion for Meropenem: Tailoring Dosing Recommendations for Chinese Critically Ill Patients on Continuous Renal Replacement Therapy with Consideration for Renal Function Author: Peng, Yaru; Liu, Yalan; Cheng, Zeneng; Zhang, Qiang; Xie, Feifan; Zhu, Sucui; Li, Sanwang Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 1105-1117. DOI: 10.2147/DDDT.S489603 PubMed DOI |
9. | Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine Author: Li, Mengyi; Huang, Siyong; Li, Jiabao; Hu, Xiao; Chen, Jisheng Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 1231-1247. DOI: 10.2147/DDDT.S499848 PubMed DOI |
10. | Enteric-Coated Aspirin Induces Small Intestinal Injury via the Nrf2/Gpx4 Pathway: A Promising Model for Chronic Enteropathy Author: Zhang, Mingyu; Xia, Suhong; Feng, Lina; Han, Xu; Zhang, Yu; Huang, Yujie; Liu, Yiran; Zhao, Kai; Guan, Jialun; Tian, Dean; Liao, Jiazhi; Yu, Yan Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2025; Vol. 19, Issue , pp. 891-910. DOI: 10.2147/DDDT.S493049 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室